News
A piece of long-awaited good news for fitness wearable maker Jawbone -- $165 million in new equity funding -- came with two more pieces of bad news: a subsequent drop in valuation and the departure of its recently hired president Sameer Samat, who returned to Google.
Samsung may be launching a new fitness tracking smartwatch soon, according to Sammobile.
About two weeks after reports of it shutting down surfaced, HealthSpot, which offered telemedicine kiosks for workplace and retail locations, has filed for Chapter 7 bankruptcy liquidation, according to a report in Columbia Business First.
While Under Armour, Apple, and Weight Watchers, have all, to varying degrees, become more involved in the calorie-tracking mobile app space, Lose It, one of the original innovators, has been quietly chugging along, capping its funding at $7 million because, according to CEO Charles Teague, the company has been profitable since at least last March.
UK-based Babylon, a remote care company, has raised $25 million in a round led by Investment AB Kinnevik with participation from Hoxton Ventures, Innocent Drinks cofounders Richard Reed, Adam Balon, and Jon Wright, as well as Deepmind cofounders Demis Hassabis and Mustafa Suleyman.
The wearable space is evolving to the point where the difference between smartwatches and fitness trackers will be one of branding and aesthetics, rather than functionality, according to a new report from Juniper Research.
Healthcare IT funding, spread across 574 deals, reached $4.
The FTC’s PrivacyCon, an all day event that included presentations and discussions from a number of privacy researchers, one presentation focused on the data privacy risks associated with direct to consumer genomic data services.
Call9, which offers emergency care via video visits to nursing homes, raised $10 million in a round led by Index Ventures with participation from Y Combinator Partner Ali Rowghani, previously an exec at Pixar and Twitter; Palantir Cofounder Joe Lonsdal; and 23andMe CEO Anne Wojcicki.
Senseonics, a Germantown, Maryland-based company working on a longterm implantable continuous glucose monitor, has filed to go public with an IPO that, for now at least, is valued at $51.